Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 530-549

  Kenda, Benoit M ^a   Matagne, Alain C ^b   Talaga, Patrice E ^a   Pasau, Patrick M ^a   Differding, Edmond ^a   Lallemand, Bénédicte I ^a   Frycia, Anne M ^a   Moureau, Florence G ^a   Klitgaard, Henrik V ^b   Gillard, Michel R ^c   Fuks, Bruno ^c   Michel, Philippe ^a  

^a Pharma Sector   (Belgium)

^b Preclinical CNS Research   (Belgium)

^c Chemin du Foriest   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 OXO 4 PROPYLPYRROLIDIN 1 YL)BUTANAMIDE; 2 [4 (IODOMETHYL) 2 OXO 1 PYRROLIDINYL]BUTANAMIDE; 2 OXOPYRROLIDINE; 2 PYRROLIDONE DERIVATIVE; ACYCLIC HYDROCARBON SUBSTITUENT; AMIDE; BEMEGRIDE; BRIVARACETAM; ETHOSUXIMIDE; ETHYL DERIVATIVE; ETIRACETAM; FUNCTIONAL GROUP; LACTAM; NEW DRUG; PENTETRAZOLE; PENTOBARBITAL; PIPERIDINE DERIVATIVE; PIRACETAM; PYRROLIDONE BUTANAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; AUDIOGENIC SEIZURE; BINDING AFFINITY; BINDING SITE; CLINICAL TRIAL; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; HUMAN; HYDROPHOBICITY; LEVETIRACETAM BINDING SITE; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ACOUSTIC STIMULATION; AMIDES; ANIMALS; ANTICONVULSANTS; BINDING SITES; BUTYRIC ACIDS; CACO-2 CELLS; CEREBRAL CORTEX; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; MALE; MICE; MICE, INBRED DBA; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PIRACETAM; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9144238050     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030913e     Document Type: Article

References (72)

1. Hauser, W. A. Overview: Epidemiology, Pathology, and Genetics in Epilepsy: A Comprehensive Textbook Lippincott-Raven Publishers: Philadelphia, 1997; pp 11-13.
2. McNamara, J. O. Emerging Insights into the Genesis of Epilepsy. Nature 1999, 399, A15-A22.
3. Dreyfuss, F. E. and France, C. J. Classification of Epileptic Seizures and the Epilepsies and Drugs of Choice for their Treatment in Antiepileptic Drugs Pharmacology and Therapeutics Handbook of Experimental Pharmacology; Springer: Berlin, 1999; pp 1-15.
4. Kwan, P.; Brodie, M. J. Early Identification of Refractory Epilepsy. N. Engl. J. Med. 2000, 342, 314-319.
5. Löscher, W.; Potschka, H. Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs. J. Pharmacol. Exp. Ther. 2002, 301, 7-14.
6. Greenwood, R. S. Adverse Effects of Antiepileptic Drugs. Epilepsia 2000, 41, S42-S52.
7. Löscher, W. Current Status and Future Directions in the Pharmacotherapy of Epilepsy. Trends Pharmacol. Sci. 2002, 23, 113-118.
8. Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Loiseau, P.; Perucca, E. Progress Report on New Antiepileptic Drugs: A Summary of the Sixth Eilat Conference (Eilat VI). Epilepsy Res. 2002, 51, 31-71.
9. Patsalos, P. N. Anti-Epileptic Drugs: Newly Licensed and Under Development. Curr. Opin. CPNS Invest. Drugs 1999, 5, 549-562. Beghi, E. The Use of Anticonvulsants in Neurological Conditions Other Than Epilepsy-A Review of the Evidence from Randomised Controlled Trials. CNS Drugs 1999, 11, 61-82.
10. Patsalos, P. N. Anti-Epileptic Drugs: Newly Licensed and Under Development. Curr. Opin. CPNS Invest. Drugs 1999, 5, 549-562. Beghi, E. The Use of Anticonvulsants in Neurological Conditions Other Than Epilepsy-A Review of the Evidence from Randomised Controlled Trials. CNS Drugs 1999, 11, 61-82.
11. Grant, R.; Shorvon, S. D. Efficacy and Tolerability of 1000-4000 mg per Day of Levetiracetam as Add-on Therapy in Patients with Refractory Epilepsy. Epilepsy Res. 2000, 42, 89-95.
12. Shorvon, S. D.; Lowenthal, A.; Janz, D.; Bielen, E.; Loiseau, P. Multicenter Double-Blind, Randomized, Placebo-Controlled Trial of Levetiracetam as Add-on Therapy in Patients with Refractory Partial Seizures. Epilepsia 2000, 41, 1179-1186
13. Shorvon, S. Pyrrolidone Derivatives. Lancet 2001, 358, 1885-1892.
14. Klitgaard, H.; Matagne, A.; Gobert, J.; Wülfert, E. Evidence for a Unique Profile of Levetiracetam in Rodent Models of Seizures an Epilepsy. Eur. J. Pharmacol. 1998, 353, 191-206.
15. th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; pp 419-427.
16. Noyer M.; Gillard M.; Matagne A. H.; Henichart, JP.; Wulfert E. The Novel Antiepileptic Drug Levetiracetam (ucb L059) Appears to Act Via a Specific Binding Site in CNS Membranes. Eur. J. Pharmacol. 1995, 286, 137-146.
17. Gobert, J.; Geerts, J.-P.; Bodson, G. Patent EP 0162036, 1985
18. Glozman, O. M.; Voronina, T. A.; Orlova, E. K.; Eshcheryoka, L. M.; Rakhmankulova, I. K.; Kazanskaya, A. A.; Smirnov, L. D.; Rostock, S.; Siegemund, H. Synthesis and Pharmacological Activity of Amidoximes of (2-Oxopyrrolidino)Alkanoic Acids and O-Acyl Derivatives. Khim.-Farm. Zh. 1989, 23, 1147-1152.
19. For the various approach to Levetiracetam see: Mealy, N. E.; Castañer, J.; Prous, J. Levetiracetam. Drugs Future 1994, 19, 111.
20. The formation of the mixed anhydride between ethyl chloroformiate and 8 must occurred below -20 °C in order to prevent its decomposition into the corresponding ethyl ester 22.
21. Gouliaev, A. H.; Monster, J. B.; Vedso, M.; Senning, A. Synthetic and Analytical Aspects of the Chemistry of Piracetam-Type Substituted Pyrrolidines. A Review. Org. Prep. Proceed. Int. 1995, 27, 273-303.
22. Ballini, R.; Bosica, G.; Damiani, M.; Righi, P. Nitroalkanes as a new Source of 2-Alkylidene-1,4-Diols, in Two Steps. Tetrahedron 1999, 55, 13451-13456.
23. Moffet, R. B. 5,5-Dimethyl-2-Pyrrolidone. Org. Synth. 1952, Coll. Vol. IV, 357-359.
24. Satzinger, G.; Hartenstein, J. Cyclic sulphonyloxyimides. Patent US 4152326, 1979.
25. Moffet, R. B.; White, J. J. Substituted Pyrrolidines and Pyrrolidylethanols. J. Org. Chem. 1952, 17, 407-412.
26. Marson, C. M.; Fallah, A. Preparation of γ- and δ-Lactams by Ring Closure of β,γ-Unsaturated Amides Using Trifluoromethane-sulfonic Acid. Tetrahedron Lett. 1994, 35, 293-296.
27. Kanno, O.; Miyauchi, M.; Shibayama, T.; Ohya, S.; Kawamoto, I. Synthesis and Biological Evaluation of New Oral Carbapenems with 1-Methyl-5-oxopyrrolidin-3-yl-thio Moiety J. Antibiot. Chem. 1999, 52, 900-907.
28. Konas, D. W.; Coward, J. K. Electrophilic Fluorination of Pyroglutamic Acid Derivatives: Application of Substrate-Dependent Reactivity and Diastereoselectivity to the Synthesis of Optically Active 4-Fluoroglutamic Acids. J. Org. Chem. 2001, 66, 8831-8842.
29. Abdel, M.; Harris, B. D.; Maryanoff, C. A. A Reductive Amination-Lactamisation Procedure Using Borohydride Reagents. Synlett 1994, 81-83.
30. Ho, T.-L.; Wong, C. M. A Simplified procedure for Enamine Alkylation Synth. Commun. 1974, 4, 147-149.
31. Stork, G.; Brizzolara, A.; Landesman, H.; Szmuszkovicz, J.; Terrel, R. The Enamine Alkylation and Acylation of Carbonyl Compounds. J. Am. Chem. Soc. 1963, 88, 207-222.
32. Amruta, R.; Hsiang, B. C. H.; Latifi, T. N.; Hill, M. W.; Woodward, K. E.; Rothman, S. M.; Ferrendelli, J. A.; Covey, D. F. 3,3-Dialkyl- and 3-Alkyl-3-Benzyl-Substituted 2-Pyrrolidinones: A New Class of Anticonvulsant Agents. J. Med. Chem. 1996, 39, 1898-1906.
33. Bourguignon, J. J.; Schoenfelder, A.; Schmitt, M.; Wermuth, C. G.; Hechler, V.; Charlier, B.; Maitre, M. Analogues of γ-Hydroxybutyric Acid. Synthesis and Binding Studies. J. Med. Chem. 1988, 31, 893-897.
34. Bourguignon, J. J.; Wermuth, C. G. Lactone Chemistry. Synthesis of β-Substituted, γ-Functionalized Butanolides and Butenolides and Succinaldehydic Acids From Glyoxylic Acid. J. Org. Chem. 1981, 46, 4889-4898.
35. Street, L. J.; Baker, R.; Book, T.; Kneen, C. O.; MacLeod, A. M.; Merchant, K. J.; Showell, G. A.; Saunders, J.; Herbert, R. H.; Freedman, S. B.; Harley, E. A. Synthesis and Biological Activity of 1,2,4-Oxadiazole Derivatives: Highly Potent and Efficacious Agonists for Cortical Muscarinic Receptors. J. Med. Chem. 1990, 33, 2690-2697.
36. Ninomiya, K.; Shiori, T.; Yamada, S. Diphenyl Phosphorazidate (DPPA). A New Convenient Reagent for a Modified Curtius Reaction. Tetrahedron 1974, 30, 2151-2157.
37. Gobert, J.; Giurgea, C.; Geerts, J.-P.; Bodson, G. (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide. Patent EP 0165919, 1985.
38. Goel, O. P.; Seamans, R. E. The Synthesis of 4-Chlorobutyric Acids Esters From γ-Butyrolactone. Synthesis 1973, 538-539.
39. Mazzini, C.; Lebreton, J.; Alphand, V.; Furstoss, R. A Chemoenzymic Strategy for the Synthesis of Enantiopure (R)-(-)-Baclofen. Tetrahedron Lett. 1998, 38(7), 1195-1196.
40. Olah, G. A.; Narang, S. C.; Gupta, B. G. B.; Malhotra, R. Transformation with TMSCl-NaI in Situ Generation of TMSI. J. Org. Chem. 1979, 44, 1247-1250.
41. Alexakis, A.; Berlan, J.; Besace, Y. Organocopper Conjugate Addition Reaction in the Presence of Trimethylchlorosilane. Tetrahedron Lett. 1986, 27, 1047-1050.
42. Lalami, K.; Dhal, R.; Brown, E. A Simple Preparation or R(+)-β-Butanolide, and Its Use in the Total Synthesis of Naturally Occurring Dibenzylbutanolide Lignans. Heterocycles 1988, 27, 1131-1134.
43. Yamamoto, H.; Furuta, K.; Misumi, A.; Mori, A.; Ikeda, N. A New Cyclopentanone Annulation of α-Bromomethyl Acrylate. Tetrahedron Lett. 1984, 25, 669-670.
44. Danishefsky, S.; Singh, R. K. A Highly Activated Cyclopropane for Homoconjugate Reactions. J. Am. Chem. Soc. 1975, 97, 3239-3241.
45. Danishefsky, S.; Singh, R. K. Preparation of Activated Cyclopropanes by Phase Transfert Alkylation. J. Org. Chem. 1975, 40, 2669-2670.
46. Leblanc, J.-P.; Gibson, H. W. Open Chain Reissert Compounds: One-Pot Synthesis and Utility in Synthesis of Unsymmetrical Imides, Alpha-Acylamino Carboxamides, Imidazolinones, and Hydantoins. J. Org. Chem. 1994, 59, 1072-1077.
47. Rodebaugh, R.; Fraser-reid, B.; Geysen, H. M. A New O-Nitrobenzyl Photocleavable Linker for Solid Phase. Tetrahedron Lett. 1997, 38, 7653-7656.
48. Löscher, W.; Schmidt, D. Which Animal Models Should Be Used in the Search for New Antiepileptic Drugs? A Proposal Based on Experimental and Clinical Considerations. Epilepsy Res. 1986, 2, 145-181.
49. Rosenberg, D. R.; Wright, B. A.; Gershon, S. Cognitive Enhancing Agents or the Treatment of Senile Dementia of the Alzheimer's Type. Drugs Today 1990, 26, 449-471.
50. Hill, M. W.; de la Cruz, M. A. M.; Covey, D. F.; Rothman, S. M. Effects of Anticonvulsant Lactams on in vitro Seizures in the Hippocampal Slice Preparation. Epilepsy Res. 1999, 37, 121-131.
51. Hill, M. W.; Reddy, A.; Covey, D. F.; Rothman, S. M. Inhibition of Voltage-Dependent Sodium Channels by the Anticonvulsant γ-Aminobutyric Acid Type A Receptor Modulator, 3-Benzyl-3-Ethyl-2-Piperidinone. J. Pharmacol. Exp. Ther. 1998, 285, 1303-1309.
52. Reddy, P. A.; Woodward, K. E.; MsIlheran, S. M.; Hsiang, B. C. H.; Latifi, T. N.; Hill, M. W.; Rothman, S. M.; Ferrendelli, J. A.; Covey, D. F. Synthesis and Anticonvulsant Activities of 3,3-Dialkyl and 3-Alkyl-3-Benzyl-2-Piperidinones (δ-Valerolactams) and hexahydro-2H-azepin-2-ones (ε-Caprolactams). J. Med. Chem. 1997, 40, 44-49.
53. 2+ Currents. Seizure 2001, 10, 279-286.
54. Dömling, A.; Ugi, I. Multicomponent Reactions with Isocyanides. Angew. Chem. Int. Ed. 2000, 39, 3168-3210.
55. (a) Matagne, A.; Margineanu, D.-G.; Kenda, B.; Michel, P.; Klitgaard, H. ucb 34714, a new pyrrolidone derivative, reveals potent activity in in vitro and in vivo models of epilepsy. Presented at the 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA, November 8-12, 2003; Poster 634.19.
56. (b) De Ryck, M.; Matagne, A.; Kenda, B.; Michel, P.; Klitgaard, H. ucb 34714, a new pyrrolidone derivative, antagonizes harmaline-induced tremor in rats: Comparison to drugs for essential tremor and anti-epileptic drugs. Presented at the 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA, November 8-12, 2003; Poster 634.20.
57. (c) Lamberty, Y.; Ardid, D.; Eschalier, A.; Alloui, A.; Segal, J.; Matagne, A.; Kenda, B.; Michel, P.; Klitgaard, H. ucb 34714, a new pyrrolidone derivative, is effective in two models of human neuropathy in the rat: Comparison to gabapentin. Presented at the 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA, November 8-12, 2003; Poster 586.8.
58. 3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur. J. Pharmacol. 2003, 478, 1-9.
59. Houston, J. B. Utility of in vitro Drug Metabolism Data in Predicting in vivo Metabolic Clearance. Biochem. Pharmacol. 1994, 47, 1469-1479.
60. The apical to basolateral flux was measured by incubation with Caco-2 cells at the final concentration of 20 μM (up to 3 h incubation).
61. Pharmacokinetic parameters were calculated according to the noncompartmental model, using the Kinetica 2000 package, version 3.0 (InnaPhase Corp., Philadelphia, PA 19103).
62. Hardin, K. E.; Clement, B. A.; Moreno, L.; Peter-Kalinic, J. Synthesis of Some Polyfunctionalized Bicyclo[3.3.1]Nonane-2,9-Diones and Bicyclo[4.3.1]Decane-2,9-Dione. J. Org. Chem. 1981, 46, 940-948.
63. Chemical and biological data for this compound are described in the Supporting Information.
64. Commercon, A.; Bourgain, M.; Delaumeny, M.; Normant, J. F.; Villieras, J. Substitution of Allylic Ether by Organomagnesium in the Presence of Copper. Tetrahedron Lett. 1975, 3833-3836.
65. Hajicek, J.; Trojanek, J. Synthesis of 2-Allyl-2-Ethylsuccinic Anhydride. Collect. Czech. Chem. Commun. 1981, 46, 1262-1271.
66. Thomas, K.; Janowitz, A.; Reissig, H.-U. A Flexible Synthesis of Methyl 4-Oxobutanoates and Their Derivatives. Synthesis 1990, 43-47.
67. Hogg, J. H., Ollmann, I. R., Wetterholm, A., Andberg, M. B., Haeggström, J., Samuelsson, J. B., Wong, C.-H. Probing the Activities and Mechanisms of Leukotriene A4 Hydrolase with Synthetic Inhibitors Chem. Eur. J. 1998, 4, 1698-1713.
68. Miller, D. D., Hsu, F.-L., Ruffolo, R. R., Patil, P. N. Stereochemical Studies of Adrenergic Drugs. Optically Active Derivatives of Imidazolines. J. Med. Chem. 1976, 19, 1382-1384.
69. Jones, G.; Wood, J. The Synthesis of 9-Azasteroids-II. Synthesis of β-cyano- and β-carbethoxy-3- and 4-oxo-1,2,3,4,5,6-hexahydro benzo[C]quinolizine. Tetrahedron 1965, 21, 2961-2966.
70. Noyes, W. A.; Irving, J. C. Synthesis of β-Methyladipic Acid J. Am. Chem. Soc. 1903, 25, 1093-1096.
71. Chu, D. T.; Claiborne, A. K.; Clement, J. J.; Plattner, J. J. Synthesis and Antibacterial Activity of Novel 6-Fluoro-7-(gem-disubstituted-piperazin-1-yl)-Quinolines. Can. J. Chem. 1992, 70, 1328-1337.
72. Morren, H. N-Substituted Lactams. Patent US 3,459,738, 1969.